JeanMarie Guenot, PH.D. is the current President and CEO of Amphivena Therapeutics, Inc. She has more than 20 years experience in the fields of pharmaceutical and biotechnology commerce. Her work experiences produced her skills in public and private pharmaceutical R&D, business development and corporate and commercial development, just to list a few of her accomplishments.
She earned her Ph. D. from the University of California, San Francisco, and her MBA from The Wharton School at the University of Pennsylvania. She has substantial and noteworthy expertise in building or restructuring companies. All of which is detailed on Jeanmarie Guenot’s Facebook page here https://www.facebook.com/jeanmarie.guenot.9
Dr. Guenot founded, built and ran SKS Ocular. This start-up ophthalmic company focused on unique drug delivery technologies for glaucoma, macular degeneration and ocular inflammation. She was also a business advisor for Hoffmann-La Roche, stationed in Basel and Shanghai.
While she was Vice President of Corporate & Business development at PDL BioPharma, she led the licensing, merger and acquisition management. She has been in on the ground floor negotiations of multi-million dollar equity investments that brought a collaboration between Phase 2 cancer and autoimmune disease drug candidates and the labs that are developing first-in-class antibody therapies.
JeanMarie Guenot has a portfolio of management experience in the areas of oncology, cardiovascular diseases, autoimmune diseases and neurology and ophthalmic diseases. Her training in physical and medicinal chemistry has been the foundation for her creation of Amphivena. Her company, Amphivena, is developing bi-functional antibody therapy to address blood cancer medical needs that are heretofore unmet by current medical standards.
The mission of Amphivena is to destroy and exterminate blood cancers with a breakthrough therapy that employs the patient’s own immune system. Their research shows that it is possible for tumor cells and their precursors to be eliminated. Amphivena aims to restore to patients the basic cellular stability needed for proper blood formation, function and circulation.
Jeanmarie Guenot and Amphivena recently announced a partnership with Takeda for just that purpose:
JeanMarie Guenot and Amphivena have forged coalitions and partnerships that combine the strengths, knowledge and resources of the industry with academic partners into a focused network. This integrated network is committed and passionate about developing the best and most innovative therapy for patients.